Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations (AcSé)
Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
Sponsor: Fondation ARC
Listed as NCT02304809, this PHASE2 trial focuses on Hematologic Cancers and Metastatic Cancers and remains ongoing. Sponsored by Fondation ARC, it has been updated 10 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2022 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Apr 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Nov 2019 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fondation ARC
- Hoffmann-La Roche
- National Cancer Institute, France
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .